checkAd

     194  0 Kommentare Sanofi completes Kiadis acquisition - Seite 3

    For more information:

    Kiadis:
    Maryann Cimino, Director Investor Relations
    & Corporate Affairs
    Tel: +1 (617) 710 7305
    m.cimino@kiadis.com

    Kiadis Media Relations Contacts
    LifeSpring Life Sciences Communication:
    Leon Melens (Amsterdam)
    Tel: +31 (20) 538 16 427
    lmelens@lifespring.nl

    Optimum Strategic Communications:
    Mary Clark, Supriya Mathur
    Tel: +44 (203) 950 9144
    kiadis@optimumcomms.com
    Sanofi:
    Sanofi Media Relations Contact
    Ashleigh Koss
    Tel.: +1 (908) 205 2572
    ashleigh.koss@sanofi.com

    Sanofi Investor Relations Contacts Paris
    Eva Schaefer-Jansen
    Arnaud Delepine
    Yvonne Naughton

    Sanofi Investor Relations Contacts North America
    Felix Lauscher
    Fara Berkowitz
    Suzanne Greco

    IR main line:
    Tel.: +33 (1) 53 77 45 45
    ir@sanofi.com

    About Kiadis
    Founded in 1997, Kiadis is committed to developing innovative cell-based medicines for patients with life-threatening diseases. With headquarters in Amsterdam, The Netherlands, and offices and activities across the United States, Kiadis is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

    Kiadis is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.kiadis.com.

    About Sanofi
    Sanofi is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. Sanofi prevents illness with vaccines and provides innovative treatments to fight pain and ease suffering. Sanofi stands by the few who suffer from rare diseases and the millions with long-term chronic conditions.

    With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

    Sanofi, Empowering Life.

    Kiadis forward-looking statements
    Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis’ or, as appropriate, Kiadis’ officers’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

    Seite 3 von 5




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Sanofi completes Kiadis acquisition - Seite 3 This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”) in connection with the public offer by the Offeror for all the issued and outstanding ordinary shares in the …